Deep learning enters the beauty industry

May 24, 2016

Insilico Medicine to present their results in applying deep learning to biomarker development and cosmetics applications at INNOCOS World Beauty Innovation Summit in Vienna 9-10th of June. INNOCOS is one of the largest annual events in the beauty industry bringing together top experts from many areas of research, R&D heads of the cosmetics conglomerates, innovation and strategy professionals and digital media experts.

In addition to heading Insilico Medicine, Inc, a big data analytics company focused on applying advanced signaling pathway activation analysis and deep learning methods to biomarker and drug discovery in cancer and age-related diseases, Alex Zhavoronkov, PhD is the co-founder and principal scientist of Youth Laboratories, a company focusing on applying machine learning methods to evaluating the condition of human skin and general health status using multimodal inputs. The company developed an app called RYNKL, a mobile app for evaluating the effectiveness of various anti-aging interventions by analyzing "wrinkleness" and other parameters. The app was developed using funds from a Kickstarter crowdfunding campaign and is now being extensively tested and improved. The company also developed a platform for running online beauty competitions, where humans are evaluated by a panel of robot judges. Teams of programmers also compete on the development of most innovative algorithms to evaluate humans.

"One of my goals in life is to minimize unnecessary animal testing in areas, where computer simulations can be even more relevant to humans. Serendipitously, some of our approaches find surprising new applications in the beauty industry, which has moved away from human testing and is moving towards personalizing cosmetics and beauty products. We are happy to present our research results to a very relevant audience at this major industry event", said Alex Zhavoronkov, CEO of Insilico Medicine, Inc.

Insilico Medicine scientists recently published a paper by Putin et al, titled "Deep biomarkers of human aging: Application of deep neural networks to biomarker development" in Aging, one of the highest-impact journals in the field and have multiple publications in review. Both published and unpublished data will be presented at the event.

Artificial intelligence is entering every aspect of our daily life. Deep learning systems are already outperforming humans in image and text recognition and we would like to bring some of the most innovative players like Insilico Medicine, who dare to work with gene expression, imaging and drug data to find novel ways to keep us healthy, young and beautiful", said Irina Kremlin, director of INNOCOS.
-end-
About Insilico Medicine

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AI division the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

InSilico Medicine, Inc.

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.